Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02097095 |
Recruitment Status :
Completed
First Posted : March 26, 2014
Last Update Posted : February 1, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Tuberculosis |
Study Type : | Observational |
Actual Enrollment : | 3253 participants |
Observational Model: | Cohort |
Time Perspective: | Other |
Official Title: | Substudy of GSK Protocol TB-018: Collection and Storage of Biological Samples for Evaluation of Correlates of Tuberculosis |
Study Start Date : | August 2014 |
Actual Primary Completion Date : | November 30, 2016 |
Actual Study Completion Date : | November 30, 2016 |

Group/Cohort |
---|
Vaccine group
TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
|
Placebo Comparator
Placebo administered on study TB-018
|
- Collect and store biological samples for future use to evaluate potential biological markers correlated to the risk for tuberculosis. [ Time Frame: 36 months in parallel with main study TB-018 (NCT01755598). ]Additional blood samples will be collected from participants that have agreed to be in this sub-study of TB-018 (NCT01755598).
- Collect and store biological samples for future use to evaluate immune correlates of protection from tuberculosis in subjects vaccinated with GSK 692342 (M72/AS01E). [ Time Frame: 36 months in parallel with main study TB-018 (NCT01755598). ]
Biospecimen Retention: Samples With DNA
Specimens for this sub-study are collected from an interventional Phase 2 study (TB-018 see NCT 01755598) and later analyzed for correlates of risk to tuberculosis.
PBMC/Plasma; Whole Blood cell count; Intracellular RNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
To be eligible for this sub-study, subjects must be enrolled in TB-018 and provide separate written informed consent for C-041-972. See NCT 01755598 for inclusion criteria into TB-018.
Exclusion criteria:
To be eligible for this sub-study, subjects must be enrolled in TB-018 and provide separate written informed consent for C-041-972. See NCT 01755598 for exclusion criteria into TB-018.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02097095
Study Director: | Bernard Landry, MS | Aeras |
Responsible Party: | Aeras |
ClinicalTrials.gov Identifier: | NCT02097095 |
Other Study ID Numbers: |
C-041-972 |
First Posted: | March 26, 2014 Key Record Dates |
Last Update Posted: | February 1, 2017 |
Last Verified: | January 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Correlates of risk TB Tuberculosis Sub-study TB-018 |
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections |
Bacterial Infections Bacterial Infections and Mycoses Infections |